PLoSONE 14(9):e0223104.https://doi.org/10.1371/journal.pone.0223104.
The survey centering on reasons behind community resistance was conducted in Butembo in November during a time of Ebola transmission. A researcher from Catholic University of Graben in Butembo and collaborators at the University o...f Alberta in Edmonton published their findings on Sep 26 in PLOS One.
To spark focus group discussions, the researchers used an 18-item questionnaire based on similar ones used during West Africa's outbreak in Guinea, where community resistance and episodes of violence also complicated the outbreak response.
Participants were a convenience sample of 670 adults from the region who were recruited by medical students at Catholic University of Graben. Those surveyed included clinicians, community members, and displaced persons.
more
Int J Crit Illn Inj Sci. 2012 May-Aug; 2(2): 82–97.
doi: 10.4103/2229-5151.97273
PMCID: PMC3401822
PMID: 22837896
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
The document covers: introduction on contact tracing in the Ebola response; general considerations for contact tracing; case definition; planning and preparation; personnel; implementation, and tools for contact tracing.
The goal of this contingency plan for El Nino related epidemics is to contribute to the reduction in mortality and morbidity associated with El Nino epidemic threats by ensuring that appropriate systems to support health emergency preparedness, timely response and post disaster recovery and mitigati...on are in place at the national, district, health facility and community levels in Rwanda.
more
Trop Med Int Health. 2015 Apr; 20(4): 448–454. Open Access
This study was carried out to better understand the local beliefs and practices likely to enhance or hinder efforts to respond to the Ebola Virus Disease outbreak in Liberia.
Globalization and Health201612:53 DOI: 10.1186/s12992-016-0194-4
A Situational Assessment and Five-YearAction Plan for the Africa CDC Strengthening Regional Public Health Institutions and Capacity for Surveillance and Response Program
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
This threat assessment addresses the implications of the ongoing Marburg virus disease (MVD) outbreak in
Rwanda for the European Union/European Economic Area (EU/EEA). MVD is a severe disease in humans and,
although uncommon, it has the potential to cause epidemics with significant case fatality. ...All recorded MVD
outbreaks to date have originated in Africa. MVD is not an airborne disease and is considered not to be
contagious before symptoms appear. Direct contact with the blood and other body fluids of infected people
and animals or indirect contact with contaminated surfaces and materials like clothing, bedding and medical
equipment is required for transmission. The risk of infection is minimised when proper infection prevention and
control precautions are strictly followed. There is no approved treatment or vaccine for MVD; however, several
pharmaceuticals and candidate MVD vaccines are under investigation.
more